Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT06956716
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
Clinical Study to Evaluate the Safety and Efficacy of Personalized Tumor Neoantigen mRNA Therapy in Combination With PD-1 Antibody and Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma
Sponsor: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions
Advanced Intrahepatic Cholangiocarcinoma
Interventions
Gemcitabine + cisplatin (GP) Sintilimab injection individualized anti-tumor new antigen iNeo-Vac-R01 injection
Updated 1 time since 2025 Last updated: Apr 30, 2025 Started: Apr 9, 2025 Primary completion: Apr 1, 2027 Completion: Apr 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Advanced Intrahepatic Cholangiocarcinoma, this trial is actively recruiting participants. The trial is conducted by Hangzhou Neoantigen Therapeutics Co., Ltd. and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Hangzhou Neoantigen Therapeutics Co., Ltd.
- Zhejiang University
Data source: Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .